Grifols S.A. - Asset Resilience Ratio
Grifols S.A. (GRF) has an Asset Resilience Ratio of 0.04% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GRF working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Grifols S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GRF current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Grifols S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Grifols S.A. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.11 Million | 0.04% |
| Total Liquid Assets | €7.11 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Grifols S.A. maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grifols S.A. Industry Peers by Asset Resilience Ratio
Compare Grifols S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Grifols S.A. (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Grifols S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | €24.18 Million ≈ $28.27 Million |
€21.41 Billion ≈ $25.02 Billion |
-0.43pp |
| 2023-12-31 | 0.54% | €116.14 Million ≈ $135.78 Million |
€21.44 Billion ≈ $25.07 Billion |
+0.34pp |
| 2022-12-31 | 0.20% | €43.26 Million ≈ $50.58 Million |
€21.53 Billion ≈ $25.18 Billion |
-10.35pp |
| 2021-12-31 | 10.55% | €2.03 Billion ≈ $2.37 Billion |
€19.23 Billion ≈ $22.49 Billion |
+9.60pp |
| 2020-12-31 | 0.95% | €145.74 Million ≈ $170.38 Million |
€15.27 Billion ≈ $17.86 Billion |
-10.16pp |
| 2019-12-31 | 11.11% | €1.73 Billion ≈ $2.02 Billion |
€15.54 Billion ≈ $18.17 Billion |
+11.11pp |
| 2018-12-31 | 0.01% | €822.00K ≈ $961.00K |
€12.48 Billion ≈ $14.59 Billion |
+0.00pp |
| 2017-12-31 | 0.01% | €702.00K ≈ $820.71K |
€10.92 Billion ≈ $12.77 Billion |
0.00pp |
| 2016-12-31 | 0.01% | €957.00K ≈ $1.12 Million |
€10.13 Billion ≈ $11.84 Billion |
+0.00pp |
| 2015-12-31 | 0.01% | €509.00K ≈ $595.07K |
€9.60 Billion ≈ $11.23 Billion |
0.00pp |
| 2014-12-31 | 0.01% | €476.00K ≈ $556.49K |
€8.45 Billion ≈ $9.88 Billion |
+0.00pp |
| 2013-12-31 | 0.00% | €232.00K ≈ $271.23K |
€5.84 Billion ≈ $6.83 Billion |
-0.29pp |
| 2011-12-31 | 0.29% | €16.90 Million ≈ $19.76 Million |
€5.81 Billion ≈ $6.79 Billion |
-0.39pp |
| 2010-12-31 | 0.69% | €12.95 Million ≈ $15.14 Million |
€1.89 Billion ≈ $2.21 Billion |
+0.19pp |
| 2009-12-31 | 0.50% | €8.22 Million ≈ $9.61 Million |
€1.66 Billion ≈ $1.94 Billion |
-0.07pp |
| 2008-12-31 | 0.56% | €6.66 Million ≈ $7.78 Million |
€1.18 Billion ≈ $1.38 Billion |
-0.19pp |
| 2007-12-31 | 0.75% | €7.08 Million ≈ $8.28 Million |
€939.57 Million ≈ $1.10 Billion |
+0.07pp |
| 2006-12-31 | 0.68% | €6.23 Million ≈ $7.29 Million |
€913.67 Million ≈ $1.07 Billion |
+0.60pp |
| 2005-12-31 | 0.08% | €661.00K ≈ $772.78K |
€821.68 Million ≈ $960.63 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more